Abiomed Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed or view top-rated stocks.

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abiomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Abiomed.

Abiomed, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Tuesday, August, 3rd. The medical equipment provider reported $1.41 EPS for the quarter, beating the Zacks' consensus estimate of $1.06 by $0.35. The medical equipment provider earned $252.59 million during the quarter, compared to the consensus estimate of $243.81 million. Abiomed had a trailing twelve-month return on equity of 16.35% and a net margin of 16.51%.
View Abiomed's earnings history.

Abiomed's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABMD shares have increased by 134.3% and is now trading at $354.13.
View which stocks have been most impacted by COVID-19.

Abiomed updated its FY 2022 earnings guidance on Wednesday, September, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.03 billion-$1.05 billion, compared to the consensus revenue estimate of $1.02 billion.

4 equities research analysts have issued 1 year price targets for Abiomed's shares. Their forecasts range from $245.00 to $425.00. On average, they anticipate Abiomed's stock price to reach $363.75 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price.
View analysts' price targets for Abiomed or view top-rated stocks among Wall Street analysts.

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Some companies that are related to Abiomed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of ABMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Abiomed's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.75%), BlackRock Inc. (9.24%), Baillie Gifford & Co. (8.01%), State Street Corp (4.31%), Primecap Management Co. CA (4.09%) and Renaissance Technologies LLC (3.70%). Company insiders that own Abiomed stock include Andrew J Greenfield, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Jackson Square Partners LLC, Renaissance Technologies LLC, Wells Fargo & Company MN, Primecap Management Co. CA, Brown Capital Management LLC, Jupiter Asset Management Ltd., and Villere ST Denis J & Co. LLC. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed or view top insider-selling stocks.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Ownership Capital B.V., Macquarie Group Ltd., Baillie Gifford & Co., Amundi, Vanguard Group Inc., Legal & General Group Plc, UBS Asset Management Americas Inc., and Marathon Asset Management LLP.
View insider buying and selling activity for Abiomed or or view top insider-buying stocks.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABMD stock can currently be purchased for approximately $354.13.

Abiomed has a market capitalization of $16.07 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.

Abiomed employs 1,725 workers across the globe.

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

Abiomed was founded in 1981.

The official website for Abiomed is www.abiomed.com.

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at (978) 646-1400 or via email at [email protected]